Rapid Titration With Intravenous Oxycodone for Severe Cancer Pain and Oral Conversion Ratio

被引:7
|
作者
Mercadante, Sebastiano [1 ]
Adile, Claudio
Ferrera, Patrizia
Lo Cascio, Alessio
Casuccio, Alessandra
机构
[1] La Maddalena Canc Ctr, Main Reg Ctr Pain Relief & Support Palliat Care, Via San Lorenzo 312, I-90146 Palermo, Italy
关键词
Cancer pain; Intravenous oxycodone; Opioids; Dose titration; Palliative care; MORPHINE; INTENSITY;
D O I
10.1016/j.jpainsymman.2022.09.004
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Context. to assess a dose titration with intravenous oxycodone to achieve rapid pain relief of cancer pain of severe intensity. The second objective was to provide a conversion ratio with the oral route.Methods. Cancer patients admitted for severe pain were prospectively assessed. At admission (T0) previous opioid doses were recorded. Edmonton symptom assessment scale (ESAS) was collected from T0 until the conclusion of the observation. Intravenous boluses of oxycodone were given until the initial signs of significant analgesia were detected. The effective dose was multiplied for six and given as intravenous continuous infusion. When the patient was considered stabilized the intravenous daily dose was converted to oral oxycodone using an initial ratio of 1:2. Subsequently, doses of oral oxycodone were changed according to the clinical situation.Results. Twenty-nine patients were examined. A mean effective bolus dose of oxycodone was 9.5 mg (SD 8.0) allowed to achieve a meaningful pain relief in a mean of 10.4 minutes (SD 3.3). The mean initial and the final infusion doses were 51.0 mg/day (standard deviation 40.9) and 69.7 mg/day ( standard deviation76.6), respectively. A significant change in pain intensity was observed at the different time intervals (P<0.0005). Conversion to oral route occurred after a mean of 2.7 days (standard deviation1.2) of intravenous oxycodone. The final mean conversion ratio was 1:2,12 ( standard deviation0.36).Conclusion. Rapid intravenous oxycodone dose titration resulted in rapid pain relief. The intravenous-oral conversion ratio of 1:2 is reliable. Further studies are necessary to confirm this preliminary observation. J Pain Symptom Manage 2022;64:532-536.(c) 2022 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:532 / 536
页数:5
相关论文
共 50 条
  • [11] Reply to the letter to the editor 'Small repeated boluses are unreliable to provide rapid analgesia with intravenous morphine titration and mislead conversion ratio to oral morphine' by Mercadante
    Fallon, M.
    Ripamonti, C. I.
    ANNALS OF ONCOLOGY, 2018, 29 (10) : 2148 - 2149
  • [12] The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain
    Lasheen, Wael
    Walsh, Declan
    Mahmoud, Fade
    Sarhill, Nabeel
    Rivera, Nilo
    Davis, Mellar
    Lagman, Ruth
    Legrand, Susan
    PALLIATIVE MEDICINE, 2010, 24 (01) : 9 - 16
  • [13] Modified glasgow prognostic score predicting high conversion ratio in opioid switching from oral oxycodone to transdermal fentanyl in patients with cancer pain
    Jia, Shu-Shan
    Shang, Li
    Li, Ming-E
    Zhao, Dong-Mei
    Xu, Wen-Hua
    Wang, Yao-Qi
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (05): : 7606 - 7612
  • [14] Oxycodone - first choice medicine for severe cancer pain
    Dzierzanowski, Tomasz
    Cialkowska-Rysz, Aleksandra
    MEDYCYNA PALIATYWNA-PALLIATIVE MEDICINE, 2010, 2 (03): : 123 - 131
  • [15] A 12-hour rapid titration method for cancer pain: a randomized, controlled, open-label study
    Liang, Jianmiao
    Chen, Lifu
    Yang, Shuang
    Zhang, Hua
    Li, Limei
    Chen, Zecheng
    Zhang, Shunda
    Xian, Haibing
    Tang, Yicong
    Deng, Yanming
    Feng, Weineng
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (01) : 88 - 96
  • [16] Rapid titration with oral sustained-release morphine plus subcutaneous morphine in a multi-center, randomized control study of cancer patients with moderate to severe cancer pain
    Sun, Yu
    Wei, Hao
    Yu, Min
    Zheng, Rujun
    Li, Junying
    Fu, Yan
    Zheng, Yuzhu
    Zhang, Xi
    Shou, Feng
    Zhou, Jin
    Yao, Wenxiu
    Chen, Ping
    Liu, Dingyi
    Jia, Yuming
    Fu, Yu
    Wang, Yan
    Zhu, Jiang
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (11) : 1303 - 1310
  • [17] Controlled Release of Oxycodone as an Opioid Titration for Cancer Pain Relief: A Retrospective Study
    Zhao, Shen
    Xu, Chunwei
    Lin, Rongbo
    MEDICAL SCIENCE MONITOR, 2020, 26
  • [18] Efficacy and safety of immediate-release oxycodone combined with sustained-release oxycodone titration in opioid-tolerant patients with moderate to severe cancer pain
    Wu, Shusheng
    Xie, Jun
    Cheng, Gang
    Ding, Shunan
    Li, Wanping
    Xu, Yuliang
    Chen, Xiaosi
    Xing, Peng
    He, Yifu
    SIGNA VITAE, 2024, 20 (10) : 72 - 80
  • [19] Influencing factors of end-of-dose failure in patients with cancer pain after oral oxycodone sustained-release tablets: a retrospective, case-control study
    Huang, Hang-Xing
    Liu, Ke-Ke
    Zhang, Lu
    Huang, Ya-Min
    Liu, Wen-Hui
    Xiao, Jian
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (06) : 932 - 941
  • [20] Factors Predicting Requirement of High-dose Transdermal Fentanyl in Opioid Switching From Oral Morphine or Oxycodone in Patients With Cancer Pain
    Kanbayashi, Yuko
    Hosokawa, Toyoshi
    Okamoto, Kousuke
    Fujimoto, Sawako
    Konishi, Hideyuki
    Otsuji, Eigo
    Yoshikawa, Toshikazu
    Takagi, Tatsuya
    Miki, Tsuneharu
    Taniwaki, Masafumi
    CLINICAL JOURNAL OF PAIN, 2011, 27 (08) : 664 - 667